Take an anti-inflammatory medication alongside standard chemotherapy and immunotherapy

Back to Intrahepatic Cholangiocarcinoma (Icc) trials

Recruiting

What is this trial?

This study is testing whether adding celecoxib—an anti-inflammatory medication you take by mouth—to standard cancer treatment can help people with advanced intrahepatic cholangiocarcinoma (a type of liver cancer) live longer without their cancer progressing. Right now, doctors treat this cancer with immunotherapy combined with chemotherapy, but results vary from person to person. This trial adds the medication to see if it improves how well the standard treatment works.

Current treatment for advanced liver cancer works, but it doesn't work equally well for everyone. Researchers believe that adding this medication might help the immune system work better against the cancer, especially in patients whose tumors have a certain protein marker (called CK5/6) that suggests they might benefit from this approach.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with intrahepatic cholangiocarcinoma that cannot be surgically removed or has spread
you have not received any systemic (whole-body) chemotherapy or immunotherapy for advanced cancer before
your tumor has the specific protein marker (CK5/6) being studied
your liver, kidneys, and bone marrow are functioning well enough to tolerate treatment
you have adequate tissue samples available from a previous biopsy for study testing

You likely don't qualify if…

you have another type of cancer (including gallbladder cancer or other bile duct cancers)
you have active gastrointestinal bleeding, peptic ulcers, or are at high risk for stomach perforation
you have had a recent heart attack, stroke, or have severe uncontrolled heart disease
you are allergic to celecoxib, NSAIDs (like ibuprofen), sulfonamides, or aspirin
you have severe liver disease (Child-Pugh class C) or severe kidney disease

What participation looks like

If you join, you'll be randomly assigned to either the standard treatment group or the group receiving the medication added to standard treatment. You'll receive intravenous chemotherapy and immunotherapy on a 21-day cycle, and if you're in the medication group, you'll take celecoxib by mouth twice daily. Throughout the trial, you'll have regular blood tests, imaging scans to check your tumor, and safety check-ins. You'll continue treatment until your cancer progresses, you experience unacceptable side effects, or you decide to stop.

Testing a new anti-inflammatory medication added to standard liver cancer treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)